ADR Biomedical Holdings Inc.

ADR120S, Inc. engages in the research, development, production, and sale of cell therapy-related medical devices in Japan. Its product pipeline includes ECCI-50 for male stress urinary incontinence, ECCL-50 for liver cirrhosis, and Cyt-006 for preventing postoperative adhesion in primary rectal cancer. The company also conducts clinical trials and research on cell therapies for various conditions, and invests in, develops, leases, and manages real estate projects and hotels, and provides real estate brokerage services. Formerly known as Cytori Cell Research Institute, Inc., it changed its name to ADR120S, Inc. in July 2025, was incorporated in 2004, and is headquartered in Chiyoda, Japan.

3750.JP▲

ADR Bio Trades on Buy Orders as Insurance Coverage Process Advances for Male Stress Urinary Incontinence Treatment Device

ADR BioMedical Holdings is trading on buy orders. The company announced on the 6th that the insurance coverage application process for its medical device for treating male stress urinary incontinence, the Selution Cell Therapy Kit SUI, has advanced to review by the specialized subcommittee on insurance medical materials of the Central Social Insurance Medical Council. This product is a medical device that uses regenerative cells derived from autologous adipose tissue, and has already obtained domestic manufacturing and marketing approval. It was approved following deliberation at the insurance coverage committee held in June. The impact on consolidated results for the fiscal year ending March 2027 is currently under review.

3750.JP ▲

トレーダーズ・ウェブ·74dRead more →